JP Morgan Chase
EPRX

JP Morgan Chase’s Eupraxia Pharmaceuticals EPRX Stock Holding History

JP Morgan Chase’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.79K Buy
+573
New +$4.61K ﹤0.01% 6925
2025
Q4 		– Sell
-16,467
Closed -$97.2K – 7849
2025
Q3 		$97.2K Sell
16,467
-2,250
-12% -$12.2K ﹤0.01% 5919
2025
Q2 		$108K Buy
18,717
+16,017
+593% +$61.5K ﹤0.01% 5569
2025
Q1 		$8.86K Buy
+2,700
New +$9.32K ﹤0.01% 6332
2024
Q3 		– Sell
-1,892
Closed -$4.88K – 7736
2024
Q2 		$4.88K Buy
+1,892
New +$5.26K ﹤0.01% 6389

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $14.8B AUM 15.12% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $24.3B AUM 29.21% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

JP Morgan Chase's EPRX Position: Q1 2026 in Review

JP Morgan Chase opened a new position in Eupraxia Pharmaceuticals (EPRX) in Q1 2026: 573 shares worth $3.79K. The stake represents ﹤0.01% of the portfolio and ranks #6925 among its holdings. This is a return to the name: JP Morgan Chase previously reported a position in EPRX as recently as Q3 2025.

JP Morgan Chase first reported a position in EPRX in Q2 2024 and has held it in 5 quarters since. The position peaked at $108K in Q2 2025. 54 funds tracked by Wall St. Rank hold EPRX as of Q1 2026.

  • JP Morgan Chase held 573 shares of Eupraxia Pharmaceuticals worth $3.79K as of Q1 2026.
  • Eupraxia Pharmaceuticals was a new JP Morgan Chase position in Q1 2026.
  • Eupraxia Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #6925 holding.
  • JP Morgan Chase first reported a position in Eupraxia Pharmaceuticals in Q2 2024 and has held it in 5 quarters since.
  • JP Morgan Chase's Eupraxia Pharmaceuticals position peaked at $108K in Q2 2025.
  • 54 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.